Updated survival analysis of two sequential prospective trials of R-MACLO-IVAM followed by maintenance for newly diagnosed mantle cell lymphoma

American Journal of Hematology
Peter J HoseinIzidore S Lossos

Abstract

A phase II trial of R-MACLO-IVAM followed by thalidomide maintenance for mantle cell lymphoma (MCL) demonstrated promising progression-free survival (PFS) and overall survival (OS) rates. Thalidomide maintenance was associated with significant toxicity and was subsequently modified to rituximab maintenance. Herein, we present updated results and follow-up. Two sequential phase II trials included chemotherapy-naïve patients with MCL up to 75 years old. Four cycles of R-MACLO-IVAM chemotherapy were delivered as previously described. Patients who achieved complete responses (CR) were eligible for thalidomide or rituximab maintenance therapy. Among 36 patients enrolled, the MCL International Prognostic Index (MIPI) was low in 53%, intermediate in 36% and high in 11%. Thirty-five patients completed at least 2 cycles of chemotherapy; 34 (94%) achieved a CR. After a median follow-up of 74.4 months, the 5-year PFS was 51% (95% CI 33-68%) and the 5-year OS was 85% (95% CI 73-97%). Two deaths occurred during the chemotherapy phase due to disease progression and neutropenic sepsis, respectively. One patient developed secondary acute myeloid leukemia after 7 years. R-MACLO-IVAM chemotherapy is effective for patients with newly diagnosed MCL.

References

Mar 1, 1995·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E ZuccaF Cavalli
Dec 16, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I F KhouriR Champlin
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
Sep 8, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jorge E RomagueraFernando F Cabanillas
Sep 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Veronica FernàndezAndreas Rosenwald
Oct 27, 2007·Blood·Eva HosterUNKNOWN European Mantle Cell Lymphoma Network
Feb 28, 2009·British Journal of Haematology·Thomas M HabermannJoseph M Tuscano
Aug 10, 2012·The New England Journal of Medicine·H C Kluin-NelemansM H Dreyling
Mar 19, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S H BernsteinR I Fisher

❮ Previous
Next ❯

Citations

Apr 14, 2017·Hematology/oncology and Stem Cell Therapy·Jose D Sandoval-SusBijal D Shah
Apr 10, 2021·Archives of Pathology & Laboratory Medicine·Jessica Alvarez-LesmesJulio Poveda

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.